AIM: To investigate the clinicopathologic features of patients with extra-gastrointestinal stromal tumors (EGISTs) in South Korea. METHODS: A total of 51 patients with an EGIST were identified. The clinicopathologic features, including sex, age, location, tumor size, histology, mitotic rate, immunohistochemical features, genetic status and survival data, were analyzed. RESULTS: The median age was 55 years (range: 29-80 years), and male:female ratio was 1:1.04. The most common site was in the mesentery (n = 15) followed by the retroperitoneum (n = 13) and omentum (n = 8). The median tumor size was 9.0 cm (range: 2.6-30.0 cm) and the median mitotic rate was 5.0/50HPF. (1/50 - 185/50). KIT was analyzed in 16, which revealed 10 cases with wild-type KIT and 6 cases with an exon 11 mutation. Among 51 patients, 31 patients had undergone surgery, and 10 had unresectable disease and had taken palliative imatinib, which resulted in 22.7 mo of progression-free survival. Of the patients who had undergone surgery, 18 did not take adjuvant imatinib, and 8 of these were categorized as "high risk" according to the risk criteria. However, the relapse-free survival was not different (P = 0.157) between two groups. CONCLUSION: Because the biologic behaviors of GISTs differ according to the location of the tumor, a more stratified strategy is required for managing EGISTs including incorporation of molecular features.
AIM: To investigate the clinicopathologic features of patients with extra-gastrointestinal stromal tumors (EGISTs) in South Korea. METHODS: A total of 51 patients with an EGIST were identified. The clinicopathologic features, including sex, age, location, tumor size, histology, mitotic rate, immunohistochemical features, genetic status and survival data, were analyzed. RESULTS: The median age was 55 years (range: 29-80 years), and male:female ratio was 1:1.04. The most common site was in the mesentery (n = 15) followed by the retroperitoneum (n = 13) and omentum (n = 8). The median tumor size was 9.0 cm (range: 2.6-30.0 cm) and the median mitotic rate was 5.0/50HPF. (1/50 - 185/50). KIT was analyzed in 16, which revealed 10 cases with wild-type KIT and 6 cases with an exon 11 mutation. Among 51 patients, 31 patients had undergone surgery, and 10 had unresectable disease and had taken palliative imatinib, which resulted in 22.7 mo of progression-free survival. Of the patients who had undergone surgery, 18 did not take adjuvant imatinib, and 8 of these were categorized as "high risk" according to the risk criteria. However, the relapse-free survival was not different (P = 0.157) between two groups. CONCLUSION: Because the biologic behaviors of GISTs differ according to the location of the tumor, a more stratified strategy is required for managing EGISTs including incorporation of molecular features.
Authors: Mee-Yon Cho; Jin Hee Sohn; Joon Mee Kim; Kyoung-Mee Kim; Young Su Park; Woo Ho Kim; Jin Sook Jung; Eun Sun Jung; So-Young Jin; Dae Young Kang; Jae Bok Park; Ho Sung Park; You Duck Choi; Sun Hee Sung; Young-Bae Kim; Hogeun Kim; Young-Kyung Bae; Miseon Kang; Hee Jin Chang; Yang Seok Chae; Hee Eun Lee; Do Youn Park; Youn Soo Lee; Yun Kyung Kang; Hye Kyung Kim; Hee-Kyung Chang; Soon Won Hong; Young Hee Choi; Okran Shin; MiJin Gu; Youn Wha Kim; Gwang Il Kim; Sei Jin Chang Journal: J Korean Med Sci Date: 2010-05-24 Impact factor: 2.153
Authors: Brian K P Goh; Pierce K H Chow; Wai-Ming Yap; Sittampalam M Kesavan; In-Chin Song; Pradeep G Paul; Boon-Swee Ooi; Yaw-Fui A Chung; Wai-Keong Wong Journal: Ann Surg Oncol Date: 2008-06-11 Impact factor: 5.344
Authors: Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher Journal: Science Date: 2003-01-09 Impact factor: 47.728
Authors: Jong Kyung Park; Seung Hye Choi; Seong Lee; Ki Ouk Min; Sang Seob Yun; Hae Myung Jeon Journal: J Korean Med Sci Date: 2004-10 Impact factor: 2.153
Authors: Le Li; Zhi Quan Hu; Chun Guang Yang; Jia Hua Gan; Ji Hua Tian; Chun Jin Ke; Xing Zeng Journal: J Int Med Res Date: 2021-05 Impact factor: 1.671
Authors: Clara Kimie Miyahira; Miguel Bonfitto; Jéssyca Fernanda de Lima Farto; Annelise de Figueiredo Calili; Nathalia Rabello da Silva Sousa; Ana Paula de Figueiredo Calili Journal: Case Rep Surg Date: 2018-05-09